Makis William, Baghli Ilyes, Martinez Pierrick
Alberta Health Services, Cross Cancer Institute, Edmonton, AB, Canada.
International Society for Orthomolecular Medicine, Toronto, ON, Canada.
Case Rep Oncol. 2025 May 26;18(1):856-863. doi: 10.1159/000546362. eCollection 2025 Jan-Dec.
Fenbendazole (FBZ), an inexpensive and widely accessible antiparasitic drug used in veterinary medicine, has garnered growing interest for its potential as an anticancer therapy. Preclinical studies suggest that FBZ exerts its anticancer effects through a wide variety of mechanisms. While FBZ has shown promise both in vitro and in vivo studies, clinical evidence supporting its use and efficacy in treating metastatic cancer is currently limited.
This report highlights 3 cases of patients with advanced cancer - including breast, prostate, and melanoma. Two patients achieved complete remission, and one achieved near-complete remission after incorporating FBZ into their treatment regimens alongside other therapies (excluding chemotherapy). All three patients tolerated FBZ without any reported adverse effects, and remission was sustained during follow-up periods ranging from 11 months to nearly 3 years.
FBZ demonstrates potential as a novel promising therapeutic option for repurposing in oncology. Its ability to contribute to tumor regression and achieve disease remission warrants further clinical research to establish its efficacy and optimize its use.
芬苯达唑（FBZ）是一种用于兽医学的廉价且广泛可得的抗寄生虫药物，因其作为抗癌疗法的潜力而越来越受到关注。临床前研究表明，FBZ通过多种机制发挥其抗癌作用。虽然FBZ在体外和体内研究中都显示出了前景，但目前支持其用于治疗转移性癌症的临床证据有限。
本报告重点介绍了3例晚期癌症患者——包括乳腺癌、前列腺癌和黑色素瘤患者。两名患者实现了完全缓解，一名患者在将FBZ与其他疗法（不包括化疗）一起纳入其治疗方案后实现了近乎完全缓解。所有三名患者均耐受FBZ，且未报告任何不良反应，缓解在11个月至近3年的随访期内持续存在。
FBZ作为一种有前景的新型肿瘤学重新利用治疗选择显示出潜力。其促进肿瘤消退和实现疾病缓解的能力值得进一步的临床研究，以确定其疗效并优化其使用。
